CoinWorld reports that Tigermed states that with industry recovery and demand rebound, domestic innovative drug clinical operation services are expected to gradually improve this year. The company's net new order amount in 2025 is projected to reach 10.16 billion yuan, a year-on-year increase of 20.7%, with the average unit price of new contracts stabilizing. As a leading domestic clinical CRO, the company is expected to benefit from increased industry concentration and market expansion.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin